Aprea Therapeutics Announces Presentation of Preclinical Data on Pipeline Programs at the AACR 2023 Annual Meeting
Aprea Therapeutics, Inc. (Nasdaq: APRE) announced the selection of its abstract on preclinical programs ATRN-119 and ATRN-W1051 for presentation at the AACR 2023 Annual Meeting in Orlando, Florida, scheduled for April 14-19, 2023. The poster, titled 'ATRN-119 and ATRN-W1051: Novel and potentially well tolerated ATR and WEE1 inhibitors for targeted cancer treatment,' will be presented on April 19 at 9:00 am ET, focusing on DNA damage response pathways in cancer treatment. Aprea is committed to developing synthetic lethality cancer therapeutics, with ATRN-119 currently in clinical stages for solid tumors and plans for WEE1 inhibitor IND submission.
- Abstract on ATRN-119 and ATRN-W1051 selected for presentation at AACR 2023, highlighting company research.
- Focus on innovative cancer therapies targeting DNA damage response could appeal to investors.
- None.
DOYLESTOWN, Pa., March 16, 2023 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE) (“Aprea”, or the “Company”), a biopharmaceutical company focused on developing novel synthetic lethality-based cancer therapeutics targeting DNA damage response (DDR) pathways, today announced that an abstract on its preclinical programs, ATRN-119 and ATRN-W1051, has been selected for presentation as a poster at the American Association for Cancer Research (AACR) 2023 Annual Meeting, being held April 14-19, 2023, in Orlando, Florida.
Details for the presentation are as follows:
Poster Title: ATRN-119 and ATRN-W1051: Novel and potentially well tolerated ATR and WEE1 inhibitors for targeted cancer treatment
Date & Time: Wednesday, April 19, 2023 at 9:00 am ET
Session Category & Title: Experimental and Molecular Therapeutics – DNA Damage Response
About Aprea Therapeutics, Inc.
Aprea Therapeutics, Inc. is a biopharmaceutical company headquartered in Doylestown, Pennsylvania, focused on developing and commercializing novel synthetic lethality-based cancer therapeutics targeting a critical pathway and some of the most central targets in DDR and cancer progression. The Company’s lead program is ATRN-119, a clinical-stage small molecule ATR inhibitor being developed for solid tumor indications. Our WEE1 inhibitor is being advanced to IND submission. For more information, please visit the company website at www.aprea.com.
The Company may use, and intends to use, its investor relations website at https://ir.aprea.com/ as a means of disclosing material nonpublic information and for complying with its disclosure obligations under Regulation FD.
Forward Looking Statement
Certain information contained in this press release includes “forward-looking statements”, within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, related to our study analyses, clinical trials, regulatory submissions, and projected cash position. We may, in some cases use terms such as “future,” “predicts,” “believes,” “potential,” “continue,” “anticipates,” “estimates,” “expects,” “plans,” “intends,” “targeting,” “confidence,” “may,” “could,” “might,” “likely,” “will,” “should” or other words that convey uncertainty of the future events or outcomes to identify these forward-looking statements. Our forward-looking statements are based on current beliefs and expectations of our management team and on information currently available to management that involve risks, potential changes in circumstances, assumptions, and uncertainties. All statements contained in this press release other than statements of historical fact are forward-looking statements, including statements regarding our ability to develop, commercialize and achieve market acceptance of our current and planned products and services, our research and development efforts, and other matters regarding our business strategies, use of capital, results of operations and financial position, and plans and objectives for future operations. Any or all of the forward-looking statements may turn out to be wrong or be affected by inaccurate assumptions we might make or by known or unknown risks and uncertainties. These forward-looking statements are subject to risks and uncertainties including risks related to the success and timing of our clinical trials or other studies, risks associated with the coronavirus pandemic and the other risks set forth in our filings with the U.S. Securities and Exchange Commission. For all these reasons, actual results and developments could be materially different from those expressed in or implied by our forward-looking statements. You are cautioned not to place undue reliance on these forward-looking statements, which are made only as of the date of this press release. We undertake no obligation to update such forward-looking statements for any reason, except as required by law.
Source: Aprea Therapeutics, Inc.
Investors and Media:
aprea@argotpartners.com
212-600-1902
FAQ
What are ATRN-119 and ATRN-W1051?
When is Aprea's presentation at the AACR 2023 Annual Meeting?
What is the significance of the AACR presentation for Aprea?
What is the focus of Aprea's research?
